Detalhe da pesquisa
1.
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Gynecol Oncol
; 182: 124-131, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38262235
2.
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Oncologist
; 28(7): e488-e492, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36943382
3.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Oncologist
; 28(7): e498-e507, 2023 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37023705
4.
Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer.
Ann Surg Oncol
; 30(13): 8144-8155, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37710139
5.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36075393
6.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Oncologist
; 26(3): e382-e393, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33098195
7.
Antibody-drug conjugates for ovarian cancer: current clinical development.
Curr Opin Obstet Gynecol
; 31(1): 18-23, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30531606
8.
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.
Breast Cancer Res Treat
; 148(3): 563-70, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25385180
9.
Blunt chest trauma.
J Trauma Nurs
; 21(6): 282-4; quiz 285-6, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25397335
10.
BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute.
PLoS One
; 18(6): e0286998, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37310942
11.
Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Cancer Res Commun
; 3(12): 2585-2595, 2023 12 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38032111
12.
HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.
Breast Cancer
; 30(5): 796-801, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37326930
13.
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer.
J Clin Med
; 12(5)2023 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36902693
14.
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Ther Adv Med Oncol
; 15: 17588359231210675, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38028143
15.
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
Cancers (Basel)
; 14(17)2022 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36077811
16.
Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.
JCO Precis Oncol
; 6: e2100239, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35357903
17.
Differentiation therapy of leukemia: 3 decades of development.
Blood
; 113(16): 3655-65, 2009 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-19221035
18.
Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.
J Clin Med
; 9(6)2020 Jun 24.
Artigo
Inglês
| MEDLINE | ID: mdl-32599960
19.
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
Cancer Chemother Pharmacol
; 85(3): 501-507, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31641845
20.
Strategies to Improve Participation of Older Adults in Cancer Research.
J Clin Med
; 9(5)2020 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-32455877